Jakubowitz Law
Business Minds. Legal Insight.

We combine large firm expertise with small firm attention. Our clients can expect the best results and the most personal experience.

Jakubowitz Law IS HERE TO HELP SHAREHOLDERS WHO PURCHASED Silverback Therapeutics, Inc. (SBTX)

(i) Silverback’s lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050’s commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

If you incurred a loss on SBTX stocks purchased (a) common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about December 3, 2020 and/or (b) securities between December 3, 2020 and September 10, 2021, both dates inclusive, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Western District of Washington, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until January 4, 2022 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.

Enter the following information for this class action case- the deadline is approaching.

See If you Qualify for Monetary Reward

Loss Submission Form

Submitting your information does not create an attorney-client relationship and you are giving us your express consent to contact you by email, text message, SMS, or call you by telephone.